Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments

The promise of cell and gene therapies is being realized as new products emerge to treat diseases once considered intractable. These treatments are emerging amidst reports of patients being injured by unproven “stem cell” interventions. At this juncture, it is vital to be supporting the continued de...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells translational medicine 2020-05, Vol.9 (5), p.547-553
Main Authors: Lomax, Geoffrey P., Torres, Art, Millan, Maria T.
Format: Article
Language:English
Subjects:
clinical trials
ethics
Evidence-based medicine
FDA approval
Federal regulation
Gene therapy
Manufacturing
Medical societies
Patient safety
Regenerative medicine
Stem cell research
stem cell transplantation
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23
cites cdi_FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23
container_end_page 553
container_issue 5
container_start_page 547
container_title Stem cells translational medicine
container_volume 9
creator Lomax, Geoffrey P.
Torres, Art
Millan, Maria T.
description The promise of cell and gene therapies is being realized as new products emerge to treat diseases once considered intractable. These treatments are emerging amidst reports of patients being injured by unproven “stem cell” interventions. At this juncture, it is vital to be supporting the continued development of promising regenerative medicine products while protecting patients from the risks posed by unproven interventions. Various stakeholders, including governments, patient groups, medical societies, and the media, are committed to this outcome. In this perspective, we draw on our experience gained from partnerships in developing regenerative medicine products to identify technical, organizational, and ethical benchmarks for the responsible delivery of regenerative medicine treatments. These benchmarks may serve as the basis for policy interventions intended to drive the responsible delivery of stem cell and regenerative medicine products. Our particular focus is on a California‐based policy, but the suggested benchmarks are broadly applicable to national and international jurisdictions.
doi_str_mv 10.1002/sctm.19-0377
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_938502015cfa44eabc10b6895bd38f45</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737028637</galeid><doaj_id>oai_doaj_org_article_938502015cfa44eabc10b6895bd38f45</doaj_id><sourcerecordid>A737028637</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23</originalsourceid><addsrcrecordid>eNp9kktv1DAQgCMEolXpjTOKxIXDbhm_YocDUlXxqFQJBOVsOfZk61USL7ZD1X-Pw5aFcsAXe-xP33hGU1XPCZwRAPo62TyekXYNTMpH1TElQq4boeDx4dzwo-o0pS2U1bRNS-FpdcQocKCCH1fuC27mwWR0qzri4E034Ko2kyvRbs5L-Kb-HENGm-udyR6nnOpbn2_qefJ9iGOdcsFNdKkuYYlwrC0OQ50jmjwu_LPqSW-GhKf3-0n17f2764uP66tPHy4vzq_WVrSMrhkQJAKx6cACMT0yBLSSM2KF6EXHO-yp49g4ooRDQRsuleOiM04qhpSdVJd7rwtmq3fRjybe6WC8_nUR4kabmL0dULdMCaBAhO0N52g6S6BrVCs6x1TPRXG93bt2czeis6WOaIYH0ocvk7_Rm_BDS6KAqrYIXt0LYvg-Y8p69GlpjJkwzElTJhiAUkQW9OU_6DbMcSqtKlTLWl56AH-ojSkF-KkPJa9dpPpcMlmSNmxxrfaUjSGliP3hywT0MjN6mRlNWr3MTMFf_F3mAf49IQVge-DWD3j3X5n-enHNCG0kZT8Bby3M1w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393947430</pqid></control><display><type>article</type><title>Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments</title><source>Open Access: Oxford University Press Open Journals</source><source>Publicly Available Content (ProQuest)</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Lomax, Geoffrey P. ; Torres, Art ; Millan, Maria T.</creator><creatorcontrib>Lomax, Geoffrey P. ; Torres, Art ; Millan, Maria T.</creatorcontrib><description>The promise of cell and gene therapies is being realized as new products emerge to treat diseases once considered intractable. These treatments are emerging amidst reports of patients being injured by unproven “stem cell” interventions. At this juncture, it is vital to be supporting the continued development of promising regenerative medicine products while protecting patients from the risks posed by unproven interventions. Various stakeholders, including governments, patient groups, medical societies, and the media, are committed to this outcome. In this perspective, we draw on our experience gained from partnerships in developing regenerative medicine products to identify technical, organizational, and ethical benchmarks for the responsible delivery of regenerative medicine treatments. These benchmarks may serve as the basis for policy interventions intended to drive the responsible delivery of stem cell and regenerative medicine products. Our particular focus is on a California‐based policy, but the suggested benchmarks are broadly applicable to national and international jurisdictions.</description><identifier>ISSN: 2157-6564</identifier><identifier>ISSN: 2157-6580</identifier><identifier>EISSN: 2157-6580</identifier><identifier>DOI: 10.1002/sctm.19-0377</identifier><identifier>PMID: 32040254</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>clinical trials ; ethics ; Evidence-based medicine ; FDA approval ; Federal regulation ; Gene therapy ; Manufacturing ; Medical societies ; Patient safety ; Regenerative medicine ; Stem cell research ; stem cell transplantation ; Stem cells</subject><ispartof>Stem cells translational medicine, 2020-05, Vol.9 (5), p.547-553</ispartof><rights>2020 The Authors. published by Wiley Periodicals, Inc. on behalf of AlphaMed Press</rights><rights>2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.</rights><rights>COPYRIGHT 2020 Oxford University Press</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23</citedby><cites>FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23</cites><orcidid>0000-0003-2288-4364</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2393947430/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2393947430?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32040254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lomax, Geoffrey P.</creatorcontrib><creatorcontrib>Torres, Art</creatorcontrib><creatorcontrib>Millan, Maria T.</creatorcontrib><title>Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments</title><title>Stem cells translational medicine</title><addtitle>Stem Cells Transl Med</addtitle><description>The promise of cell and gene therapies is being realized as new products emerge to treat diseases once considered intractable. These treatments are emerging amidst reports of patients being injured by unproven “stem cell” interventions. At this juncture, it is vital to be supporting the continued development of promising regenerative medicine products while protecting patients from the risks posed by unproven interventions. Various stakeholders, including governments, patient groups, medical societies, and the media, are committed to this outcome. In this perspective, we draw on our experience gained from partnerships in developing regenerative medicine products to identify technical, organizational, and ethical benchmarks for the responsible delivery of regenerative medicine treatments. These benchmarks may serve as the basis for policy interventions intended to drive the responsible delivery of stem cell and regenerative medicine products. Our particular focus is on a California‐based policy, but the suggested benchmarks are broadly applicable to national and international jurisdictions.</description><subject>clinical trials</subject><subject>ethics</subject><subject>Evidence-based medicine</subject><subject>FDA approval</subject><subject>Federal regulation</subject><subject>Gene therapy</subject><subject>Manufacturing</subject><subject>Medical societies</subject><subject>Patient safety</subject><subject>Regenerative medicine</subject><subject>Stem cell research</subject><subject>stem cell transplantation</subject><subject>Stem cells</subject><issn>2157-6564</issn><issn>2157-6580</issn><issn>2157-6580</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kktv1DAQgCMEolXpjTOKxIXDbhm_YocDUlXxqFQJBOVsOfZk61USL7ZD1X-Pw5aFcsAXe-xP33hGU1XPCZwRAPo62TyekXYNTMpH1TElQq4boeDx4dzwo-o0pS2U1bRNS-FpdcQocKCCH1fuC27mwWR0qzri4E034Ko2kyvRbs5L-Kb-HENGm-udyR6nnOpbn2_qefJ9iGOdcsFNdKkuYYlwrC0OQ50jmjwu_LPqSW-GhKf3-0n17f2764uP66tPHy4vzq_WVrSMrhkQJAKx6cACMT0yBLSSM2KF6EXHO-yp49g4ooRDQRsuleOiM04qhpSdVJd7rwtmq3fRjybe6WC8_nUR4kabmL0dULdMCaBAhO0N52g6S6BrVCs6x1TPRXG93bt2czeis6WOaIYH0ocvk7_Rm_BDS6KAqrYIXt0LYvg-Y8p69GlpjJkwzElTJhiAUkQW9OU_6DbMcSqtKlTLWl56AH-ojSkF-KkPJa9dpPpcMlmSNmxxrfaUjSGliP3hywT0MjN6mRlNWr3MTMFf_F3mAf49IQVge-DWD3j3X5n-enHNCG0kZT8Bby3M1w</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Lomax, Geoffrey P.</creator><creator>Torres, Art</creator><creator>Millan, Maria T.</creator><general>John Wiley &amp; Sons, Inc</general><general>Oxford University Press</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2288-4364</orcidid></search><sort><creationdate>202005</creationdate><title>Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments</title><author>Lomax, Geoffrey P. ; Torres, Art ; Millan, Maria T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>clinical trials</topic><topic>ethics</topic><topic>Evidence-based medicine</topic><topic>FDA approval</topic><topic>Federal regulation</topic><topic>Gene therapy</topic><topic>Manufacturing</topic><topic>Medical societies</topic><topic>Patient safety</topic><topic>Regenerative medicine</topic><topic>Stem cell research</topic><topic>stem cell transplantation</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lomax, Geoffrey P.</creatorcontrib><creatorcontrib>Torres, Art</creatorcontrib><creatorcontrib>Millan, Maria T.</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Stem cells translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lomax, Geoffrey P.</au><au>Torres, Art</au><au>Millan, Maria T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments</atitle><jtitle>Stem cells translational medicine</jtitle><addtitle>Stem Cells Transl Med</addtitle><date>2020-05</date><risdate>2020</risdate><volume>9</volume><issue>5</issue><spage>547</spage><epage>553</epage><pages>547-553</pages><issn>2157-6564</issn><issn>2157-6580</issn><eissn>2157-6580</eissn><abstract>The promise of cell and gene therapies is being realized as new products emerge to treat diseases once considered intractable. These treatments are emerging amidst reports of patients being injured by unproven “stem cell” interventions. At this juncture, it is vital to be supporting the continued development of promising regenerative medicine products while protecting patients from the risks posed by unproven interventions. Various stakeholders, including governments, patient groups, medical societies, and the media, are committed to this outcome. In this perspective, we draw on our experience gained from partnerships in developing regenerative medicine products to identify technical, organizational, and ethical benchmarks for the responsible delivery of regenerative medicine treatments. These benchmarks may serve as the basis for policy interventions intended to drive the responsible delivery of stem cell and regenerative medicine products. Our particular focus is on a California‐based policy, but the suggested benchmarks are broadly applicable to national and international jurisdictions.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>32040254</pmid><doi>10.1002/sctm.19-0377</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2288-4364</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2157-6564
ispartof Stem cells translational medicine, 2020-05, Vol.9 (5), p.547-553
issn 2157-6564
2157-6580
2157-6580
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_938502015cfa44eabc10b6895bd38f45
source Open Access: Oxford University Press Open Journals; Publicly Available Content (ProQuest); Wiley Open Access; PubMed Central
subjects clinical trials
ethics
Evidence-based medicine
FDA approval
Federal regulation
Gene therapy
Manufacturing
Medical societies
Patient safety
Regenerative medicine
Stem cell research
stem cell transplantation
Stem cells
title Regulated, reliable, and reputable: Protect patients with uniform standards for stem cell treatments
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A39%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulated,%20reliable,%20and%20reputable:%20Protect%20patients%20with%20uniform%20standards%20for%20stem%20cell%20treatments&rft.jtitle=Stem%20cells%20translational%20medicine&rft.au=Lomax,%20Geoffrey%20P.&rft.date=2020-05&rft.volume=9&rft.issue=5&rft.spage=547&rft.epage=553&rft.pages=547-553&rft.issn=2157-6564&rft.eissn=2157-6580&rft_id=info:doi/10.1002/sctm.19-0377&rft_dat=%3Cgale_doaj_%3EA737028637%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5932-301e15ee6b0c01afe3e0ec7431c55f5b4bef2d4e6d185de526478d45bad783e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2393947430&rft_id=info:pmid/32040254&rft_galeid=A737028637&rfr_iscdi=true